Wedge Capital Management L L P NC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 16.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 285,497 shares of the company’s stock after purchasing an additional 39,609 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Johnson & Johnson were worth $36,938,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Zions Bancorporation N.A. grew its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock valued at $2,810,000 after purchasing an additional 73 shares during the period. Portland Global Advisors LLC grew its stake in shares of Johnson & Johnson by 0.9% during the 3rd quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock valued at $1,131,000 after purchasing an additional 78 shares during the period. Vishria Bird Financial Group LLC grew its stake in shares of Johnson & Johnson by 3.0% during the 2nd quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock valued at $381,000 after acquiring an additional 80 shares during the period. Alta Capital Management LLC grew its stake in shares of Johnson & Johnson by 3.9% during the 3rd quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock valued at $282,000 after acquiring an additional 82 shares during the period. Finally, G&S Capital LLC grew its stake in shares of Johnson & Johnson by 1.8% during the 3rd quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock valued at $604,000 after acquiring an additional 84 shares during the period. 72.25% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE:JNJ traded up $1.57 during mid-day trading on Friday, reaching $133.00. 4,856,974 shares of the company traded hands, compared to its average volume of 7,224,392. The company’s 50 day moving average price is $130.83 and its 200-day moving average price is $134.05. The firm has a market cap of $343.25 billion, a PE ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The business had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. During the same period in the prior year, the company posted $2.05 EPS. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, research analysts predict that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 annualized dividend and a yield of 2.86%. Johnson & Johnson’s payout ratio is 46.45%.

A number of research analysts recently issued reports on JNJ shares. Credit Suisse Group boosted their price objective on Johnson & Johnson from $158.00 to $163.00 in a research note on Thursday, October 24th. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Raymond James cut their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Finally, Wells Fargo & Co cut their price objective on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research note on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Buy” and a consensus target price of $151.64.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Front-End Load

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.